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Abstract 
MiRNAs are post-transcriptional regulators of protein expression and they bind to 
complementary sequences in the 3’UTRs of their target mRNA  either performing transcript 
degradation or translational inhibition. It is accepted that they play a role in the defect of β-
cells to secrete enough insulin so trigger type 2 diabetes mellitus (T2DM). T2DM is a 
common, complex, metabolic disorder. It can characterize with these defects; insulin 
resistance in peripheral tissues and beta‐cell dysfunction or reduced beta cell mass. Due to 
these defects blood glucose level increase. At the same time there is a real that T2DM is not 
because of  only these reasons. Also genetic actions seems to be involved in the development 
of T2DM. This project focuses on a microRNA that has been shown to be involved in 
glucose‐induced beta‐cell dysfunction. The key findings from other studies were that miR‐29a 
is up‐regulated by glucose in beta‐cells and decrease glucose‐stimulated insulin secretion by 
inducing decreased activity of the electron transport chain. Recently two publications have 
shown that microRNAs are present in the mitochondria, suggesting that microRNAs can 
regulate mitochondrial gene-expression.   So in this project the target sequence was searched 
for  miR29-a. Based on this information  it was tried to identify any targets of miR-29a in the 
mitochondrial encoded subunits of the electron transport chain. In this project we identified 
potential targets of miR-29a in: in ND6, ND5 and D-LOOP. The oligos were designed as 
having a predicted target sequence for miR29-a and transferred to a vector which has luc2 
gene. These vectors were copied in E.coli cells then transfected HEK cells for luciferase 
assay. Unfortunetly the luciferase assay’s data and t-test showed that there is no target 
sequence in ND6. During the experiments because of the unknown reasons we could not use 
other oligos ND5 and D-LOOP. But for say a certain answer this experiment must repeat. 
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ABBREVATIONS 
UTR                        Untranslated region 
ATP                        Adenosine tri‐phosphate 
CDS                        Coding sequence 
ETC                        Electron transport chain 
GDM                      Gestational diabetes mellitus 
GSIS                       Glucose‐stimulated insulin secretion 
Hsa                         Homo Sapiens 
miRNA                   MicroRNA 
miRISC                   RISC complex with miRNA 
mRNA                     Messenger RNA  
nt                             Nucleotide 
OXPOHS                 Oxidative phosphorylation 
Pre‐miR                   MicroRNA precursor 
Pri‐mIR                    Primary microRNA transcript 
RISC                         RNA Induced Silencing Complex 
Rno                           Rattus Norvegicus 
T1DM                       Type 1 Diabetes Mellitus 
T2DM                       Type 2 Diabetes Mellitus 
bp                              Base pair 
ON                            Over night 
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1. INTRODUCTION 
1.1. Diabetes Mellitus 
Diabetes Mellitus is a common metabolic disorder affecting the people. This disorder 
characterized by high blood glucose level 
[1]
. This defect related with insulin production and 
the capability of peripheral tissues insulin production 
[1,2]
.  Although diabetes mellitus is 
known by effect on carbohydrate metabolism, usually due to affects of  lipid and protein 
metabolism 
[3]
. 
There are 3 major subtypes of diabetes; type 1 diabetes (T1DM), type 2 diabetes (T2DM), 
gestational diabetes (GDM). Both Type 1 and Type 2 diabetes can trigger to reducing 
microvascular complications such as retinopathy, nephropathy and neuropathy. At the same 
time, macrovascular complications such as cardiovascular diseases including atherosclerosis 
and hypertension. Differently, T1DM is an autoimmune disease. In the world,  the epidemical  
type is T2DM 
[2]
. The T2DM has two symptoms: Insulin resistance (IR) and beta‐cell 
dysfunction 
[1]
. Several factors can promote these two defects. Such physical inactivity, long-
term exposure to various psychosocial factors, increase the body’s exposure to 
glucocorticoids, and the main stress hormones in humans. These effects are seen in 
pre‐diabetic states and act to progressively impair  glucose tolerance that  call forth T2DM 
[1,3]
. In case of T2DM, insulin producing cells hurt and insulin expression decrease because of 
beta-cell dysfunction 
[4]
. It can be obtained from these information that glucose metabolism is 
uncoupled from glucose‐ stimulated insulin secretion. The glucose stimulated insulin 
secretion  depends on beta-cell function, mostly 
[1]
. Also the beta-cell death is important for 
T2DM. Indeed beta‐cell death and the beta‐cell dysfunction seems to be connected to the each 
other 
[5]
.  It is clear that restoration of beta‐cell dysfunction or prevention of  this defects is 
admirable for treatment  of T2DM 
[3,5]
 . It is realy important to clarify and understand  
relationship between T2DM, dysfunction of beta-cells and insulin secretion for treatment of 
disease 
[5]
.  
1.2. Pancreas structure and function for diabetes mellitus 
1.2.1. Structure Of The Pancreas 
The pancreas is a lanky organ that lies behind and below the stomach (Figure 1 ). It contains 
both exocrine and endocrine tissues. The smaller part of the gland tissue is known as islets of  
Langerhans which are dispersed throughout the pancreas 
[5]
. The main cell types within the 
islets are β, α, δ, F and ε-cells that secrete hormones such as insulin, glucagon, somatostatin, 
- 9 - 
 
pancreatic polypeptide and grehlin, respectively. The role of  these cells help regulate the 
hormonal control of energy metabolism and especially  glucose homeostasis 
[6]
. 
   
 
and other nutrients out of the blood into cells 
[7]
. When blood glucose rises, insulin hormone 
released from the beta cells give rise to  glucose to enter  body cells for using energy 
production 
[1]
. Also, it stimulates transformation of glucose to glycogen in the liver at the 
required times. Another pancreatic hormone glucagon, promotes the movement of glucose 
into the blood when glucose levels are below normal level in the blood 
[6]
. It causes the 
breakdown of stored liver glycogen to glucose 
[7]
. 
Each organs and tissues are dependent on glucose for survival and specific function 
[1,3]
. On 
the other hand, hyperglycemia can cause to organ damage. In body, the level of glucose must 
regulate and stabilize, always 
[6]
. 
 
1.3. Mitochondria  in diabetes mellitus  
It is accepted that the energy-converting organelles of eucaryotes evolved from procaryotes 
that were engulfed by primitive eucaryotic cells and developed a symbiotic relationship with 
them about 1.5 x 10
9
 years ago 
[8]
. This would explain why mitochondria have their own DNA 
(mtDNA), which codes for some of their proteins 
[9]
.  
Development and pathogenesis of diabetes mellitus have been associated with  mitochondrial 
dysfunction in the related tissues 
[1]
. As follows,  glucose manufacture ATP and other 
metabolic factors in the beta-cell 
[9]
. Mitochondrial DNA (mtDNA) encodes some of the 
polypeptides of the respiratory chain. Thus it is said that mutations in mtDNA can promote to 
maternally inherited diabetes mellitus. Such as the formation of the other types diabetes this 
mutation cause  to damaged insulin secretion 
[8]
. So the effect of mtDNA on insulin secretion 
The insulin and glucagon are most 
important hormones that secreted by 
pancreas 
[1,6]
. Both play a role in 
eligible metabolism of sugars and 
starches in the body 
[6]
. Insulin 
promotes  the   movement  of    glucose  Figure1:Pancreas structure. 
 
1.2.2. Function of the pancreas 
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like that. In other different studies, using beta-cell lines the mtDNA defiency  have tested. As 
a result  lost glucose-stimulated insulin secretion was noticed when mtDNA damaged. After 
retain of the defect insulin secretion has been induced 
[9]
. Consequently, mitochondrial 
dysfunction is now widely accepted as a key player in the development of T2DM and in the 
suspend of metabolism‐secretion coupling in beta‐cell failure [1,9]. 
1.4. Mitochondrial Genes 
The mammalian mtDNAs have retained only 13 polypeptide genes, all of which encode 
essential components of OXPHOS (Figure 2 ). MtDNA also encodes the 12S and 16S rRNA 
genes and the 22 tRNA genes required for mitochondrial protein synthesis 
[9]
. 
           
Figure 2 :Mitochondrial genes and protein complexes  that are encoded by mitochondria. mtDNA encode genes 
that required for its function. But complexes are very sectional. Many domain encode by nuclear DNA. From the 
picture it is seen that ND6, ND5, ND4/4L, ND3 encode for complex 1 by mtDNA [9]. 
In insulin secretion, some defects are known as a result of mtDNA depletion/ mutation or 
depletion of mitochondrial transcription factors. The  idea  from  that TCA cycle,  ETC 
activity and mtDNA are staminal for insulin secretion and glucose metabolism in beta cells 
[1,2]
. Briefly, for the release of  insulin vesicles the ETC complexes and many proton and Ca
+2
 
channels are required 
[1]
. If some reason damage these complex or their domain the cycles 
break down. So the glucose metabolism and insulin secretion break down 
[2]
. 
1.5. MicroRNAs 
MicroRNAs  (miRNAs)  are short (about 20–22 nucleotides), endogenously produced, and 
non-coding RNAs. It has been illustrated that they have  an important role in regulating  gene 
expression and controlling several basic cellular functions 
[1]
. MicroRNAs were discovered in 
the early 1990s in a nematode, Caenorhabditis elegans, and the first identified miRNA, lin-4 
was found to play a critical role in controlling developmental timing by downregulating its 
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target, lin-14, due to the antisense complementarity 
[10]
. According to theory microRNA genes 
appear to have been added to the genome throughout evolution. This hypothesis comes from 
that miRNAs are highly conserved between organisms  
[11]
. 
 MicroRNAs have been shown to be involved in most biological pathways which are 
embryonic development, organogenesis, differentiation, proliferation, apoptosis, cell‐cycle 
regulation, secretion, viral defence and in a wide range of diseases 
[12]
. In addition, some 
miRNAs are expressed in almost all tissues and cell types, but some are highly tissue specific 
[13]
. Recently, it was demonstrated that miRNAs are both actively and passively exported and 
imported to - from the blood by neighbouring cells 
[14]
. 
1.5.1. Biogenesis and  processing microRNAs 
The miRNAs are transcribed by a RNA Polymerase into primary transcripts (Pri-miRNAs) in 
the nucleus from DNA (Figure 3). MiRNAs can  encode from mono‐ or polycistronic miRNA 
genes that  they have their own promoter and regulatory units. Also miRNAs can encode from  
introns or UTRs of protein‐coding genes for co‐regulated together with their host genes or 
other genes 
[15]
. 
            
Figure 3: miRNA biogenesis and function. Mature miRNAs occur  from a multistep process. They are first 
transcribed by RNA polymerase II (RNA pol II) as a primary miRNA (pri-miRNA) transcript. After being 
cleaved in the nucleus by the RNAse III ribonuclease, Drosha, and its cofactor Pasha, the precursor miRNA (pre-
miRNA) is exported to the cytoplasm by Exportin 5, where it is cleaved by a second RNAse III ribonuclease, 
Dicer. This 16- to 29-nucleotide-long miRNA duplex is then unwound to free the mature strand for incorporation 
into a RNA-induced silencing complex (RISC) and, based on sequence complementarity, directs translational 
repression or cleavage of its mRNA target by binding to either the 3′- or 5′-untranslated (UTR) regions [16]. 
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The mature miRNA is released and degraded in this manner guide miRNAs occur. Then, 
Dicer‐TRBP and the miRNA guide strand is assembled into the RNA‐Induced Silencing 
Complex (RISC) or when loaded with miRNA: the miRISC complex, by recruiting an 
Argonaoute (Ago) protein and other co‐factors (Figure 3) [17].  
MiRNA biogenesis and processing are highly regulated processes. The transcription of 
pri‐miRNAs regulate similar to protein‐coding mRNAs [16,17]. Also some epigenetic 
modifications are regulated by pri‐miR transcription [18]. However, the process of miRNA 
regulation and pre‐miR transport from the nucleus are not fully identified. But it is clear that 
miRNA processing and nuclear export are highly miRNA and tissue specific 
[19]
. 
1.5.2. Target specificity of microRNAs 
The RISC complex is directed by the mature miRNA for target sequence that is located in the 
3’UTR of the target gene transcripts (mRNA) in the cytoplasm. The miRNA binds to this 
sequence such as suffering bulges and wobble base‐paring. It was demonstrated that exact 
complementarity in the 5’ end of the mature miRNA, specially the nucleotides 2‐8 from the 5’ 
end of the mature miRNA. Its name is “seed sequence” that is mportant for target binding 
[19,20]. The seed is required to be exactly complementary to the 3’ end of the target sequence. It 
can be only a single nucleotide mismatch or bulge in this sequence for target recognition 
[20]
. 
There are also some factors that are important for specifity and target binding: First of all  the 
AU‐rich sequence place near the seed match additionally for co‐expressed miRNAs closeness 
of  coding sites causes to cooperative action. Further,  positioning of the target site must be 
away from the stop‐codon (leastways 15 nucleotides) and  away from the middle of long 
3’UTRs [20,21].  The most important thing for miRNAs binding, that target sequences are 
located in the 3’UTR of the exonic transcript. At the same time,  miRISC target sequences  
can locate in the coding sequences (CDS) of target mRNAs 
[22].  Targets in the 5’UTR of 
mRNAs have also been identified and may promote target up‐regulation rather than 
down‐regulation [23]. 
1.5.3. Control of gene expression and protein production by miRNAs 
MiRNAs are important regulators of gene expression at  post‐transcriptional level [13]. 
MicroRNAs can mediate both transcript degradation, deadenylation by degradation of 
translation 
[15]
. The mechanism of translational inhibition is not completely understood. But 
the miRISC complex has been shown to interact with the ribosome for stopping mRNA 
translation by inhibiting initiation 
[16,17]
. Decreases  of mRNA or protein levels by miRNAs, 
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depend on the miRNA, the target gene and the cellular and physiological context. 
Additionally mRNAs can potentially be regulated by more than one miRNA, and one miRNA 
can be regulatable for more than one  mRNA 
[16]
.  
RNA editing is also a regulative feature of miRNA functions and stability. Editing of miRNA 
sequences can lead to either decreased or increased target specificity. For this, the length of 
the complementary seed sequence is important for the level of regulation 
[24]
. 
1.5.4. Relationship Between MicroRNAs and Diabetes 
It is demonstrated that miRNAs are essential for pancreatic islet cells. When  Dicer enzyme  
knock‐out of in the developing pancreas, in all pancreatic lineages major defects are seen in 
the insulin producing beta‐cells [25]. It is obtained from several studies that under high glucose 
conditions regulation by miRNAs strongly involvement of glucose induced beta‐cell failure in 
beta‐cells or in diabetic patients [26].  
Various miRNAs might regulate relevant proteins in muscle, liver, adipocyte and  pancreas. 
For instance, loss- and gain-of-function studies show that deregulation of miR-375 influence 
insulin secretion in β- cells due to a negative effect on insulin exocytosis [27]. Moreover miR-9 
and miR-124  might be involved in the negative regulation of insulin secretion and in the 
differentiation of β-cells, respectively [28]. These three miRNAs might be involved in 
pathophysiology of the diabetes mellitus, when they are deregulated at some point 
[27,28]
. 
Potentially miRNAs even constitute targets for pharmacological treatment of T2DM. Also 
miR-34a and miR-146 are up regulated in β- cells by high fatty acid concentrations, making 
these miRNAs candidates for conveying lipotoxicity 
[29]
. 
1.5.5. Importance of miR-29 family for diabetes 
Many mammalian genomes encode four closely related miR-29 precursors. The human miR-
29 family of microRNAs has three mature members, miR-29a, miR-29b, and miR-29c. The 
miR-29 family members share a common seed region sequence and are predicted to target 
largely overlapping sets of genes 
[30]
. Several studies  confirmed miR29 families elevated 
expression in three important target tissues of insulin action: muscle, fat and liver of diabetic 
rats. The increase in miR-29 level caused insulin resistance, similar to that of incubation with 
high glucose and insulin in combination. Taken together these, the information  divulge 
crucial role of miR-29 in type 2 diabetes 
[31]
. Since the increased expression of miR-29 is 
found to decrease insulin sensitivity in muscles, hepatocytes and adipocytes, this pathway is 
suggested to constitute a negative feedback mechanism for insulin. However there might be 
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other determining factors than glucose and insulin levels, as hyperinsulinemia and 
hyperglycemia could not account for the up-regulation of miR-29c. In accordance with these 
results another study finds a 1.5 times higher concentration of miR-29a in the adipose tissue 
of rats 
[29]
. There is an idea that miR-29a is expressed strongly in INS-1E rat cells, a cell line 
from pancreatic β-cells of rats. Therefore the miR-29a and INS-1E cells are used in this 
project. An other good point that there is no divergence between the sequences of miR-29a in 
rats and humans 
[31]
. 
1.5.6. MicroRNA target identification  
In spite of miRNAs have been studied extremely for  years, only a relatively limited number 
of direct targets have been identified  
[32]
. In silico analysis are challenged mainly by some 
factors. Firstly, the short size of miRNAs is a difficulty for search and everything is not found 
about miRNA biology. Additionally, process of miRNA and its target binding forms, at the 
same time regulation of miRNA expression is not so clear and simple 
[1,18,33]
.  
The fact that the miRNA target recognition and binding are based on partial complementarity 
to their target sequences and unfortunately miRNA target recognition and binding is not yet 
fully understood  
[33]
. The most common target prediction tools are Microcosm and 
Targetscan. Pictar is also a well used prediction database but  has not been updated since 
2007. The algorithms employed by each of the two remaining target prediction tools are 
different and based on different features of miRNA biology. This also means that the 
predicted targets vary intensively  between the two databases 
[32,33]
. 
The MicroCosm target prediction uses the MiRanda algorithm. This algorithm generates a 
probability score for the target‐miRNA but shows only interaction to  3’UTRs of transcripts 
based on seed sequence complementarity 
[34]
. The features of miRNA‐target binding and the 
restrictions used in these algorithms does not accurately predict targets 
[35]
. Several hundreds 
of predicted target transcripts emerge when searching for a possible miRNA target, and 
several possible miRNAs that target mRNAs are listed when searching for miRNAs 
regulating a specific mRNA 
[34,35]
. 
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Aim Of Project 
MiRNAs have been shown to be involved in regulating signaling pathways and cellular 
functions associated with the pathogenesis of several diseases. Some miRNAs have been 
shown to be regulated by glucose in various cell types and tissues and some miRNAs have 
been shown to be involved in regulating beta‐cell functions such as insulin synthesis and 
secretion. The idea is,  identification of glucose‐regulated  miRNAs target sequences in 
mtDNA’s genes in the beta cells. This project focuses on miR-29a and to identfy a target 
sequence for miR-29a in the mitochondrially encoded subunits of the electron transport chain. 
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2. MATERIAL / METHOD 
2.1. Plasmid/Vector 
The pGL4.13[luc2/SV40] Vector encodes the luciferase reporter gene luc2 and is designed for 
high expression and reduced abnormal transcription (Figure 4). 
 
 
Figure 4 : The pGL4.13Vector circle map. 
 
The pGL4 Vectors are engineered with fewer consensus regulatory sequences and a synthetic 
gene, which has been codon optimized for mammalian expression. The pGL4.13 [luc2/ SV40]  
mean the vector contains the luc2 reporter gene and the SV40 early enhancer/promoter for use 
as an expression control or a co-reporter vector.                 
2.2. DNA-oligos 
The following DNA-oligos were ordered: 
control site,  XbaI site,  FseI site,  target site,  5nt from target 5’ 
 Oligo 1 ND5 sence: 
5’CTAGAGGTACCTAACAGCCATACTATGTCTTGGTGCAATCAGGCGG 3’ 
Oligo 2 ND5 antisence: 
5’ CCTGATTGCACCAAGACATAGTATGGCTGTTAGGTACCT 3’ 
Oligo 3 mutant ND5 sence: 
5’ CTAGAGAGCTCTAACAGCCATACTATGTCTTAGTTCAATCAGGCCGG 3’ 
Figure 5 :The Multiple Cloning Region 
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Oligo 4 mutant ND5 antisence: 
5’ CCTCAAGTAGCACAACTATAAATAGCCGCAACCCCTCGAGT 3’ 
Oligo 5 ND6 sence: 
5’ CTAGACTCGAGGGGTTGCGGCTATTTATAGTTGTGCTACTTGAGGCCGG 3’ 
Oligo 6 ND6 antisence: 
5’ CCTCAAGTAGCACAACTATAAATAGCCGCAACCCCTCGAGT 3’ 
Oligo 7 mutant ND6 sence: 
5’ CTAGACAGCTGGGGTTGCGGCTATTTATAGTTCTGTTACTTGAGGCCGG 3’ 
Oligo 8 mutant ND6 antisence: 
5’ CCTCAAGTAAGACAACTATAAATAGCCGCAACCCCAGCTGT 3’ 
Oligo 9 D-LOOP sence: 
5’ CTAGA GGGCCCCCCATGATCAACATA ACTGTGGTG ATATACAT GGCC GG 3’ 
Oligo 10 D-LOOP antisence: 
5’ CCATGTATATCACCACAGTTATGTTGATCATGGGGGGCCCT 3’ 
Oligo 11 mutant D-LOOP sence: 
5’ CTAGA GTCGAC CCCATGATCAACATA ACTGTGATTATATACATGGCC GG 3’ 
Oligo 12 mutant D-LOOP antisence: 
5’ CCATGTATATAATCACAGTTATGTTGATCATGGGGTCGACT 3’ 
 
2.2.1. Annealing of DNA-oligos 
Oligos were suspended in TE (Tris Buffer) and made a waterbath in a beaker with boiling 
water. In the other hand the annealing buffer was thawing on ice. 1 μl of each matching sense 
and anti-sense oligos were mixed together in  safelock tubes. 48 μl annealing buffer was 
added to each tube. The samples were boiled for 2 minutes and cooled down ON (over night). 
Samples are saved at -20 
o
C until use. 
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2.2.2. Phosphorylation of DNA oligos 
To an ependorf tube 2 µl annealed oligo, 1 µl T4 PNK Buffer, 1 µl ATP, 5 µl H2O AND 1 µl 
PNK enzyme were added. After incubated at 37
o
C for 30 min, incubated 10 min at 70
o
C.  
2.3. Cutting of pGL4.13 vector with Restriction Enzymes 
6,9 µl pGL4.13, 5 μl 10xNE buffer4, 0,5 μl 100x BSA, 1 µl XbaI and  2 µl FseI were mixed 
and 35 μl DNAse free water added to the mix and total volume 50 μl. Digestion was done 
XbaI and FseI and incubating 4 hours at 37
o 
C. Then heat inactivated was done for 20 minutes 
at 65
o 
C and stored at  -20
o
C until use. 
2.4. Preparation of agarose gel  
 A solution for a 0,7 % agarose gel 1,05 g agarose and 150 mL TBE buffer were mixed and it 
was melted in the microwave. After the addition of  15 µl Ethidiumbromide, the mix was 
poured into a gel cast. The gel was dried apporximetely 30 minutes at RT and additional TBE 
buffer was poured over the gel to prevent it from drying out. The gel was then sealed in 
plastic and stored at 40
o
C. 
2.5. Gel electrophoresis of digested pGL4.13 and purification of digested vector 
The 50 µl of cut vector was mixed 1:1 with loading buffer  and loaded into the wells of the gel 
25 µl in 5 wells. At 140 V, it was run. The DNA was seperated electrophoretically in  TBE 
buffer with Ethidiumbromide. The digested vectors were taken from the gel at UV room. 4 
ependorf  tubes were weighed before the band slices placed inside them. Then the eppendorfs 
were weighed again with bands. Continuation the following were added as table 1: 
 
Table 1:Volumes for purification steps and bands weight 
Empty tube’s 
Weight:1,08g 
Total  
weight 
Bands  
weight 
Volume of  
Binding buffer 
Volume of  
isopropanol 
1.tube 1,25 g 0,17 g 510 µl 255 µl 
2.tube 1,35 g 0,27 g 810 µl 405 µl 
3.tube 1,47 g 0,39 g 1170 µl 585 µl 
 
After added binding buffer, tubes were incubated 10 min at 56
o
C in the heat-shaker until all of 
the gels were dissolved. When the agarose gels were dissolved isopropanol was added as 
table1.  According to protocol, this solution was pipeted to the High Pure Filter Tube + a 
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collection tube and made cantrifuge 1 min at max speed. Following the protocol many steps 
were done like washing for getting purification vector. Hereafter concentration of purified 
vectors was measured on a Nanodrop 1000. The concentration was 26,5 ng/µl. 
2.6. Ligation of DNA oligos and pGL4.13 
The oligos were ligated into the vector with a ratio of 2 μl oligo / 3 μl vector. The negative 
control contained pGL4.13 and water. Ligation procedure followed Fermentas  Rapid Ligase 
Kit protocol. To an eppie 2 µl annealed phosphorylated oligo, 3 µl digested vector, 4 µl 5x 
Rapid Ligation Buffer, 10 µl DNAse free water, and 1µl T4 DNA Ligase enzyme were added. 
Then incubated 5 min at RT. It is done for each oligo and controls. Kept them at 4
o
C until 
used for transformation. 
2.7. Transformation of E.coli with Ligated Constructs 
A competent  E. coli culture was taken from -80
o
 C freezer and thawed in an ice bath. The 2 
mL LB medium preheated. 14 LB-100ƳAMP-plates were dried and labelled. 2 mL 7 eppies 
also were labelled for transformation. 10 µl of 10.000 times diluted vector and 10 µl from 
each ligation mixes were mixed with 100 µl competent E. coli cells. Only 10 μl of undigested 
pGL4.13 was used for the negative control because more colonies were expected when using 
this vector. Tubes were incubated for 30 minutes on ice and then exposed to heat shock for 45 
seconds at 42
o
C. Then they were incubated on ice 2 min. Continuation 250 µl preheated LB 
media was added and tubes were incubated for 30 minutes at 37
o
 C while shaking. Hereafter 
100 µl was added to LB-AMP plates from  and all of the remain solution was added to rest 
plates. Only 100 µl containing uncut vector was added to control LB rest. Plates incubated 
ON at 37
o
 C turned upside down. 
2.8. Pick Colonies and Clean-up 
The colonies were checked and relaized that most of them are uncountable because of the 
many more colonies. After some colonies were selected for checking inserts. These colonies 
were picked with a steril match and placed into new LB-Amp plates (they will be stocks) and 
into LB suspension tubes from each of the selected. The plates were sealed with parafilm and 
placed in cooling room (-4
o 
C)  with the bottom of the plate facing up. The suspension tubes 
were grown at  37
o
C on shaker ON. Thus we had 6  cleaned- up colonies from each plate. 
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2.9. Minipreps for restriction analysis and test of inserts with restriction enzymes 
Minipreps were done according to Miniprep Kit from Sigma from each of the suspension 
cultures grown ON in total 24 tubes. 
 
 
( as enzyme type), 1,4 µl BSA ( if necessary), 7 µl  from enzymes and DNAse free water 
according to total volume 70 µl were added. Then to other tubes 2 mL from constructs were 
added together 8 µl DNAse free water and 10 µl enzyme mastermix. Hereafter tubes were 
incubated 2 hours/ON for enzymes action, enzymes were inactivated 20 min at 65
o
C. To see 
fragments, 7 µl digeston mix + 7 µl loading buffer  from each tubes were loaded into a gel 
(%1) and was run. Pictures were taken after running. 
Figure 6 :The principle of how to clean-up a colony     
( streaking method) 
After obtained the DNA, restriction test was 
done. 
Table 2 : enzymes, enzyme’s cutting sites and types of  
buffers for testing inserts 
Construct Restriction 
enzyme 
cutting size NE buffer 
number 
D-LOOP ApaI 2167 (530) Neb4+BSA 
D-LOOP 
mutant 
SalI 2163 (2425) Neb3+BSA 
ND6 XhoI 2165 
(125,574) 
Neb4+BSA 
ND6 
mutant 
Pvu I 2163  
(34) 
Neb2 
 
4 enzymes mixes were made in an eppendorf 
tubes. For an eppendorf tube  14 µl 10xbuffer 
 
Figure 7 :Protocols of miniprep 
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2.10. Midiprep 
Midipreps were made according to Qiafilter plasmid midi kit from Qiagen. Precipitation 
was done as  required volumes and 96 % ethanol , 10 % sodium acetate prepared  for each 
product.  After precipitation, samples were measured on a spectrophotometer with 2 μl of 
sample in 98 μl M.Q. water. 
2.11. Transfection 
The HEK293 human kidney cells were prepared the day before, 20.000 cell/well. They 
incubated at cell lab incubator at 37
o
C , % 100 humudity and  % 5 CO2 ON. The next day 
samples were prepared, diluted required proportions according to table 3. 
Table 3 :preparation for  vector  transfection into HEK cells 
Prep 195            scrambled target           11 µL  +   190  µL H2O (RNAse free) 
Prep 197    perfect microRNA29a target      40 µL  +   61  µL  water 
Klon E                       ND6                            16 µL   +  84  µL water 
Klon F                  ND6 mutant                     23,5 µL+ 76,5 µL water 
p GL4.13                  vector                           35  µL  +  65 µL water 
beta gal            transfection  reporter        
 
After dilution, 2.5 µL from each RNAs and 6 µL from each DNAs were taken to new 
tubes for transfection. Then cell’s media was changed and added fresh media. The 
optimem medium was added to all tubes as 30 µL and waited 25 minutes. After that, 25 
µl from all sample tubes were added to the cell wells and incubated ON  at 37oC. 
2.11.1. Lipofactemine  
Lipofectamine 2000 (LF2000) is a cationic liposome derived agent, which during 
incubation with DNA forms micelles and can fuse with the INS-1E membrane. Optimem, 
a cationic liposome compatible reduced serum media, is used for the transfection. 
2.12. Luciferase assay 
The transfected cells were prepared before. The media was removed and cells were 
cleaned with PBS then the lysis buffer was added and kept on fridge. For measurement all 
required buffers and solutions were thawed or mixed. The assay was done as two steps: 
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First step was measurement of beta-gal (beta-galactosidase) level. There were 30 samples 
from cells plate. For all well duplicated reading were done so in total there were 60 
samples. It was used that luminometer machine for obtaining the luminecence levels. 
                                      
Figure 8 : this plate screen shows samples name and types. The yellow color mean: NON (nothing); the 
green color mean: NEG (negative); the orange color mean: mimic (miR29-a). Also pGL: Pgl4.13 vector, 
perf:perfect miR29-a target sequence, scr: scrambled target ( no target sequence for miR29-a), ND6: 
mtDNA encoded protein that we have designed with miR29-a predicted target sequence, mut: ND6 mutant 
(in the designed predicted target sequence there is two or three mismatch base). This same colors and names 
were used in other results. 
The reaction buffer was diluted  ratio of 1:100. For 8 mL, 80 µl stock buffer and 7920 µl 
water were mixed. As follows 4 µl cell extract (such as figure 8 ) and 100 µl galacton 
reaction buffer were mixed per each cell well. Also accelerator buffer was placed into 
machine. The most important thing was done that was set-up machine as level of high and 
low light. The sensitivity was % 100. In every measurement the machine used  150 µl 
accelerator buffer. After beta-gal step, luiseferace step was done.100 µl Luiceferase assay 
buffer (LAB) and 6 µl sample were mixed and measured on machine. For luiseferase step 
the machine was rearranged. The sensitivity was %60. 
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3. RESULT 
3.1. Design and Cloning of DNA-oligos 
Six different inserts were designed and cloned into the plasmid. The plasmid pGL4.13 
was used as a cloning vector. The following six DNA-oligos were designed: ND5, mutant 
ND5, ND6, mutant ND6, D-LOOP, mutant D-LOOP. The oligos contains the miR-29a 
target site in the 3’ UTR of their mRNA and mutants does not contains target sequence 
they have two or three mismatch base in target site that was designed. There were some 
important point in the design process. First, the binding affinity of miR-29a is important 
for the oligo, which only contains a small part of the entire 3’ UTR, is closely matched to 
that of the actual miR-29a target site of these genes. For this, the DNA oligos does not 
only contain the target site, but also 5 nt of the original sequence around it. The reason 
why only 10 extra nt were added, was to keep the oligo size to a minimum to ensure an 
effective cloning. Furthermore it is important to be able to investigate whether the cloning 
process was successful. This was carried out by designing each oligo with specific and 
unique restriction sites. To be able to eliminate other miRNAs affecting the results, all 
DNA-oligos were screened for other predicted target sites, using the TargetScan and 
MiRbase algorithms. This search identified several potential target sites for miRNAs, but 
none that are expressed in rats, mice or humans. 
Sence and antisence oligos sequences were designed and cloned into pGL4.13. The 
following restriction analysis and selection for plasmids with antibiotic resistance 
determined if they were inserted in the vector. The pGL4.13  vector contains AmpR, an 
ampicillin resistance gene. During the cloning process, the AmpR gene is used to select 
plasmids with antibiotic resistance. This was carried out by growing the cloned plasmids 
on media containing ampicillin, only allowing cells with annealed plasmids, which are 
able to express the AmpR gene, to survive. The results of the selection can be seen on 
Figure 9. 
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Figure 9: All plates are LB-AMP plates, with E. coli that E.coli cells were transfected with the  pGL4.13 
having designed oligos,  growing ON at 37°C.  A: clone  D-LOOP. B: clone D-LOOP mutant. C: clone 
ND5. D: clone  ND5 mutant.  E:clone ND6.  F: clone ND6 mutant.  G:cells+ water LB medium. J: cells+ 
water LB-AMP medium. H: uncut vector residual. K: uncut vector 100 µl. I: cut vector residual. L: cut 
vector 100 µl.   
 
As seen on Figure 9, the digested vector (I,L) has a considerably lower number of 
colonies than both the plate with the transformed E. coli and the undigested pGL4.13 
(H,K). Each colony represents E. coli cells which expresses a plasmid with the AmpR 
gene. The digested vector serves as a negative control where colonies show the 
effectiveness of the digestion procedure. Because relatively few E. coli cells survived, it 
can be assumed that the digestion was very effective. The undigested vector serves as a 
positive control as no digestion has been made, allowing for all transformed E. coli to 
express the resistance gene. Because the positive and negative controls were as expected. 
All results from the six transformations were similar and expected, and were used for the 
restriction analysis. 
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3.2.  Restriction analysis 
After selection of E. coli colonies, a restriction analysis was performed to confirm that the 
insert with the target sites were present in the constructs. We obtained colonies only for 
D-LOOP/mutant and ND6/mutant there was a confusion about ND5 plates so we had to 
remove ND5. The restriction enzymes used to cut the different oligos were Apal (D-
LOOP), Sall (D-LOOP mutant), Xhol (ND6) and PvuII (ND6 mutant). Each oligo was 
constructed to contain one unique restriction site for one of the enzymes. The introduced 
sites are also present in the plasmid pGL4.13, which makes it possible to compare both 
fragment sizes and numbers. Because each oligo has one specific site, it is also possible to 
distinguish between them among each other if needed. 
Table 4 shows the result of calculations of expected fragment sizes based on the 
restriction sites. pGL4.13 is 4641 bp. Calculations of individual fragments are based on 
the location of the restriction site in both the vector and inserts.  
 
Table 4: The restriction sites of the inserted oligos are found by calculating the distance between the 
restriction sites. In total the pGL4.13 has 4671 bp after insert. After digestion the constructs were run on an 
agarose gel.  
construct Restriction enzyme Expected fragment 
D-LOOP ApaI 1637+3034 
D-LOOP mutant SalI 262+4409 
ND6 XhoI 449+1591 
ND6 mutant PvuII 2129+2542 
  
                                                                                                                         
                                              
Figure 10: Agarose gel from digestion and electrophoresis of the four clones. The wells to the left and right 
contain: 10 μl 1kb plus DNA ladder, followed by 6 wells containing 7 μl digested mix + 7 μl loading buffer. 
All digestions were incubated for 120 minutes. The gel has been run at 120 V for  about 90 minutes. A 
depicts the D-LOOP-construct digested with ApaI, and the D-LOOP/mutant-construct digested with SalI, 
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continuously the ND6-construct digested with XhoI and the ND6/mutant-construct digested with PvuII. 
There are visible fragments at the expected size range from only two  digestions which are ND6 and ND6 
mutant. The ladder is 1 kb Plus DNA ladder from Invitrogen. 
 
Figure 10 shows the results from the gel electrophoresis of the digested clones. Each 
clone was prepared and run. There were only two digested oligo types that were ND6 and 
ND6 mutant. This discrepancy is applicable for all digestions which suggest a general 
problem, or an important problem about insertion of oligos. Maybe it was because of 
using different restriction enzymes for each plasmid, an explanation for the difference in 
digested plasmid could be that some enzymes needs a longer incubation time to cut the 
plasmid than the others. Therefore another digestion was made with longer incubation 
time, see Figure 11. 
 
                                   
Figure 11: Restriction was done ON for test is there any problem because of incubation time. The gel was 
run at 120 V for about  90 minutes. There was no differently visible bands from first digestion stil only 
ND6 and ND6 mutant. The ladder is 1 kb Plus DNA ladder from Invitrogen. 
 
Figure 11 shows the gel electrophoresis of the second digestion and electrophoresis of D-
LOOP-constructs and  ND6-constructs , using the restriction enzyme ApaI and SalI. 
There were no expected bands are visible after this second digestion for D-LOOP 
constructs, which gives validity to the hypothesis about a too short incubation period for 
enzymes in the first digestion. It did not work. Maybe the oligo were not inserted we 
could not know certainly.  In summary, the digestions of ND6 and ND6 mutant constructs 
appears to be correct in size relatively to each other. 
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3.3. Luciferase assay 
 
The primary aim of the luciferase assay was to determine, whether miR-29a interacts with 
the predicted target site from ND6 and ND6 mutant. Moreover it can show whether miR-
29a is glucose induced or not but for our  project the aim is to see the predicted target 
sequences are real or not . The target site and negative as well as positive controls were 
cloned into pGL4.13 containing luc2, the gene coding for Firefly luciferase (FF). This 
construct serves as a model, where expression of FF is a measurable indication of miR-
29a and ND6 complementation. A luciferase assay is used to measure protein expression 
and regulation. In this method FF activity is measures with the activity of beta-gal.  The 
advantage of looking at relative and not at total FF activity is that the amount of cells 
transfected and measured do not affect the results. Alternations in the ratios between FF 
and beta-gal activity reflect the effect the endogenous miR-29a exerts on the different 
constructs. The constructs are the basis for examining the predicted binding of miR-29a 
to the target site on ND6 and mutant. If miR-29a binds to the target site in the constructs, 
protein expression of the FF enzyme will be suppressed which will lower the FF/beta-gal 
ratio. The constructs containing the genes for FF and beta-gal a constitutive promoter. 
When we look the avarage of them we will have an idea for target sequence 
complementation situation (see figure 12 ).  
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Figure 12 : The figure depicts the ratio between the FireFly (FF) luciferase and beta-gal. Each column 
represents one of the transfections with pGL4.13 with insert ND6 oligo. The FF/beta-gal ratio of 
transfections with the ND6-construct is expected to lie within the range from the positive to the negative 
control. When we compare them between each other we are having a delusion. The expected results was to 
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see same or close level between perf mimic and ND6 mimic. But it was not seen like that. It was also 
expected that  scr mimic and mut ND6 mimic must show same or close level of luciferase/beta-gal avarage. 
It was approximately as expected. The positive control Perf is also different from both negative controls in 
all, which was necessary. But it is still confusing to use a control for reference everything was not expected. 
 
It was expected that the lowest FF/beta-gal ratio is obtained from transfections with the 
Perf construct, since the inserted site in the 3’UTR of luc2 is perfectly complementary to 
miR-29a. With a perfect binding, it is anticipated that miR-29a exerts the highest 
suppression of the translation of FF mRNA, acting as a positive control. Transfections 
with pGL4.13, Scr construct and ND6 mutant-constructs are expected to have similar and 
high FF/beta-gal ratios, having no target sites for miR-29a, acting as negative controls. I 
have nothing (NON) and negative (NEG) controls and of course samples. I compared 
them between each other see figure 13. 
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Figure 13: this graphs show that the results really not expected. Because it can understand from mimic 
graph, scr mimic must not to be close with ND6 mimic. Some results expected but not enough  for say the 
target sequence found.On the contrary the data tell there is no target sequence in ND6 for miR29-a. 
 
The usefull test was implemented to the data. A t-test is any statistical hypothesis test in 
which the test statistic follows a Student's t distribution if the null hypothesis is supported. 
It is most commonly applied when the test statistic would follow a normal distribution if 
the value of a scaling term in the test statistic were known ( see figure14 ).  
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t-TEST Sample 1  Sample 2  P value Significantly 
different 
 Perf 6B mimic ND6 12D mimic 0,0818 NO 
 Scr 9C mimic Mut 15E mimic 0,1490 NO 
 Scr 9C mimic ND6 12D mimic 0,0770 NO 
 Perf 6B mimic Mut 15E mimic 0,0163 YES 
 Mut 15E mimic ND6 12D mimic 0,5393 NO 
 
Figure 14 : Statistic test were implemented for  determine whether there are significant differences between 
the ratio of ND6 and the controls. However it  is obvious from the graph  Perf and pGL4.13 are lower than 
ND6. For the assay ND6 mimic  is not significantly lower than Scr mimic (P-value=0.0770) and Mut mimic 
(Pvalue=0.5393). Yet, for the assay only ND6 mutant mimic and Scr mimic was significantly different 
(Pvalue=0.0163). There is no significant difference between Scr mimic and Mut mimic in either the (P-
value=0.1490).  
Finally,  from luciferase assay graphs and related t-test it is clear that ND6 does not have 
any target sequence for miR29-a. The designed predicted target sequence is not correct. 
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4. DISCUSSION 
The hypothesis was that miR-29a is a mediator of ND6, ND5 and D-LOOP down-
regulation and promote diabetes mellitus type 2  by close oxidative phosphorylation, 
undirectly. The data shows a down-regulation of luciferase level, when the target site of 
miR29-a complement to its seed sequence for luc2 expression repression. To comment 
the results several considerations has to be taken into situation. Firstly, the experiments 
need to be replicated to obtain more representative data because every time experiments 
must be done one more for to feel certain about  each step are going accurately. In this 
project during the experiment something carried on wrongly that due to unknown some 
reasons but it does not mean the protocols wrong or experiment course wrong. Namely, to 
say a certain answer for a hypothesis, needs one more trial. But when we look the results 
from the initial it seems there was a mistake in insertion of oligos to vector step. Due to 
we could not see any band on restriction analysis gel result. Also it can based on 
restriction enzymes. Additionally the statistical tests would be more trustworth with more 
data again we need the assays replication. At the same time the controls are so impotant 
and they offer many possibilities for experiment that we had. In this project the big 
weaknesses is that not have been replicated. So it makes uncertain to conclude on the 
data. The more experiments could indicate to say if miR-29a has a target sequence in  
ND6’s mRNA. Unfortunately a sufficient answer to the main hypothesis in this project 
cannot be given. But it can say just by looking these datas ND6 does not have a target 
sequence for ND6.  
 
For the future research the existing connection to T2DM between miR-29a and ND6 
because of OXHPOS, could be motivating. Alternatively, small reinforcements could 
help illuminate the nature of the predicted target site. For example one could try to clone 
the predicted target site into the vector several times to enhance the sensitivity of the 
system and provide that one of the inserts is structurally accessible to miR-29a.  
The miRNA research is a new research area. Databases such as TargetScan and MirBase 
still provides an incomplete information of miRNAs; novel miRNAs are found 
methodically and many of the predicted target sites have just confirmed or disconfirmed. 
There is a disagreement between the idea of miRNAs being a special mechanism and 
miRNAs being crucially important in protein expression regulation. This cause to  the 
difficulty to obtain  a certain  opinion of the role of miRNAs. In that case to invastigate 
about miRNAs own regulation  being more important for future. At the same time  a 
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miRNA can bind to a protein’s mRNA and for an other protein can bind target sequence 
of 3’UTR. So it might be interesting to research other miRNAs having predicted target 
sites in the 3’UTR of ND6.  
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